Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURPASS-OPC: Finotonlimab-based induction chemoimmunotherapy plus CCRT and maintenance vs CCRT alone in iENE-positive HPV-positive oropharyngeal carcinoma
ChiCTR2600127740Phase 2Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of finotonlimab in oropharyngeal squamous cell carcinoma (OPSCC) (2 arms), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Event-Free Survival (EFS). Planned start Jul 2026; status: not yet recruiting.
02
Drugs
finotonlimab
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on ChiCTR2600127740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127740.